Heska Corporation (HSKA)
(Delayed Data from NSDQ)
$79.28 USD
+3.36 (4.43%)
Updated May 3, 2019 04:00 PM ET
After-Market: $79.10 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$79.28 USD
+3.36 (4.43%)
Updated May 3, 2019 04:00 PM ET
After-Market: $79.10 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Is SPDR S&P Health Care Equipment ETF (XHE) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XHE
Strength Seen in eXp World Holdings (EXPI): Can Its 20.7% Jump Turn into More Strength?
by Zacks Equity Research
eXp World Holdings (EXPI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Should You Invest in the SPDR S&P Health Care Equipment ETF (XHE)?
by Zacks Equity Research
Sector ETF report for XHE
Heska (HSKA) Q1 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Heska (HSKA) delivered earnings and revenue surprises of -46.88% and 7.10%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Stoke Therapeutics, Inc. (STOK) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Stoke Therapeutics, Inc. (STOK) delivered earnings and revenue surprises of 24.29% and 44.44%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Heska (HSKA) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Heska (HSKA) delivered earnings and revenue surprises of 44.74% and 3.72%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Acadia (ACHC) to Post Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Acadia Healthcare's (ACHC) fourth-quarter results are likely to reflect an increase in patient days and admissions.
Heska (HSKA) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Heska (HSKA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Heska (HSKA) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Heska (HSKA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Heska (HSKA) Moves 9.0% Higher: Will This Strength Last?
by Zacks Equity Research
Heska (HSKA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Heska (HSKA) Q3 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Heska (HSKA) delivered earnings and revenue surprises of -8.89% and 11.80%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Puma Biotech (PBYI) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Puma Biotech (PBYI) delivered earnings and revenue surprises of 90.91% and 11.09%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Sutro Biopharma, Inc. (STRO) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Sutro Biopharma, Inc. (STRO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Heska (HSKA) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Heska (HSKA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Blueprint Medicines (BPMC) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Blueprint Medicines (BPMC) delivered earnings and revenue surprises of 11.16% and 51.69%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks.com featured highlights include Heska, Tandem Diabetes Care, Credit Suisse Group, Zalando SE and Las Vegas Sands
by Zacks Equity Research
Heska, Tandem Diabetes Care, Credit Suisse Group, Zalando SE and Las Vegas Sands are part of Zacks Screen of the Week article.
Heska (HSKA) Q2 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Heska (HSKA) delivered earnings and revenue surprises of -8.11% and 6.62%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
5 Toxic Stocks That May Prove Hazardous for Your Portfolio
by Rimmi Singhi
Toxic companies are characterized by huge debt pile and are vulnerable to external shocks. Accurately identifying such stocks and getting rid of them at the right time can protect your portfolio. CS, LVS, HSKA, TNDM and ZLNDY are five such stocks.
Amgen (AMGN) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Amgen (AMGN) delivered earnings and revenue surprises of 5.68% and 0.77%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
AbCellera Biologics Inc. (ABCL) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
AbCellera Biologics Inc. (ABCL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Heska (HSKA) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Heska (HSKA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Heska (HSKA) Misses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Heska (HSKA) delivered earnings and revenue surprises of -34.15% and 3.44%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Mirum Pharmaceuticals, Inc. (MIRM) delivered earnings and revenue surprises of 15.83% and 48.59%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Regeneron (REGN) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Regeneron (REGN) delivered earnings and revenue surprises of 22.63% and 9.47%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Heska (HSKA) Q1 Earnings Expected to Decline
by Zacks Equity Research
Heska (HSKA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.